VOGX • NASDAQ
Vogenx Inc.
$29.52
Stock Details
| Market Cap | 0 |
|---|---|
| Day Change | 5.87 (24.82%) |
| Volume | 428,736 |
| Avg Volume | 304,652 |
| Price Range | 12.95-29.64 |
Overview
| Country | US |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
Company Profile
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
Financial Overview
| 52 Week High | 29.64 |
|---|---|
| 52 Week High Date | 2026-08-21 |
| 52 Week Low | 12.95 |
| 52 Week Low Date | 2026-08-12 |
| 10D Avg Trading Vol | 0.34272 |
| YTD Price Return Daily | 127.0769 |
| MTD Price Return Daily | 127.0769 |